|Bid||61.2400 x 1000|
|Ask||61.3600 x 800|
|Day's Range||60.7600 - 62.5700|
|52 Week Range||41.0600 - 96.5900|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.67|
Spark Therapeutics, Rite Aid, and Alnylam Pharmaceuticals shares have dropped recently, but that doesn't necessarily make all three stocks worth buying.
NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.
Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc, Spark Therapeutics Inc and Bluebird Bio Inc to have its specialty pharmaceutical business exclusively distribute their new gene therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
NEW YORK, NY / ACCESSWIRE / August 15, 2018 / U.S. equities snapped losses on Tuesday, as panic over Turkey’s currency eased and market participants focused on upbeat corporate earnings and strong economic ...
Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
To trade momentum biotech stocks, it's often best to follow the top experts. Using TipRanks' Top-Rated Stocks investor tool, we can see which biotech names float as Wall Street's most recommended stocks today.
Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.
Spark Therapeutics crashed Tuesday after its hemophilia A study results seemingly lagged a rival treatment from BioMarin Pharmaceutical. Spark plunged 27.8% in high volume.
Shares of Ekso Bionics saw big gains during the trading day but lost almost 11% in after-hours trading. The company reported second quarter results that didn’t hit estimates. Spark Therapeutics, Inc. shares closed down 27.83% on Tuesday, on significant trading volume compared to usual.
Biotechnology investors are no strangers to volatility, and Tuesday's price action was no exception. Followers of gene therapy companies watched one of the most popular names in the industry lose approximately one-third of its value due to patient safety concerns. As alluded to above, shares of Spark Therapeutics dropped sharply in Tuesday's trading session due to heightened patient safety concerns surrounding a hemophilia gene therapy trial.
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
Investors are pumping $50 million into Akouos Inc.’s effort to develop gene therapies for hearing loss. No drugs have been approved in the U.S. to cure hearing loss. About 37.5 million U.S. adults report some trouble hearing, according to the National Institute on Deafness and Other Communication Disorders.
China launched a rally across global markets Tuesday, with Etsy, Twilio and Illumina posting early leads in the U.S., as Disney prepared for its report after the close.
Spark Therapeutics (NASDAQ:ONCE) stock was falling hard on Tuesday following the release of its earnings report for the second quarter of 2018. Spark Therapeutics’s earnings report includes an update concerning the company’s Phase 2 trial of SPK-8011. SPK-8011 is a gene therapy the company is developing to reduce bleeding caused by hemophilia A. The results from this study found that it reduced annualized bleeding rates and annualized infusion rates in all of the 12 patients by 97%.
The company reported two patients in a study of its hemophilia A gene therapy had an adverse immune response, but with that issue addressed Spark is moving forward late-stage testing of the experimental product.
Spark Therapeutics (ONCE) delivered earnings and revenue surprises of 581.40% and -14.44%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Spark Therapeutics Inc. (ONCE) shares dropped 28% in Tuesday premarket trade after the company said two patients in its hemophilia phase 1/2 trial had a concerning immune response, one of whom was hospitalized as a result. Twelve patient total have been dosed so far in the clinical trial, which is testing the company's gene therapy SPK-9001 in patients with hemophilia B, and the therapy's effect on patients' clotting factor levels was an important outcome.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related ...